Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Feb;99(8):e19330.
doi: 10.1097/MD.0000000000019330.

Efficacy and Safety of TCM Yangxin Anshen Therapy for Insomnia: A Systematic Review and Meta-Analysis

Affiliations
Free PMC article
Meta-Analysis

Efficacy and Safety of TCM Yangxin Anshen Therapy for Insomnia: A Systematic Review and Meta-Analysis

Feizhou Li et al. Medicine (Baltimore). .
Free PMC article

Abstract

Background: Traditional Chinese Medicine (TCM) has gradually drawn the attention of clinicians as an alternative choice for insomniacs and TCM Yangxin Anshen Therapy (TYAT) is a crucial therapy of treating insomniacs. The purpose of this study was to evaluate the efficacy and safety of TYAT for insomnia.

Methods: Seven electronic databases were searched from inception to July 2019. Two authors independently identified Randomized Controlled Trials (RCTs), extracted data and assessed risk of bias by Cochrane risk bias assessment tool. Comprehensive meta-analysis was conducted with the Review Manager for eligible and appropriate studies.

Results: Fourteen trials (1549 participants) were finally included in this study. The included studies were of moderate-to-high quality. Twelve trials reported the specific methods of random sequence generation, and 4 of them used the allocation concealment. Blinding of participants and personnel were used in 7 studies, and blinding of outcome assessment was performed in 3 studies. The main meta-analysis showed: CONCLUSION:: TYAT is an effective alternative therapy for insomnia, and its clinical application appears safe. The conclusions of this paper have a certain reference value for further research and clinical practice.

Trial registration number: PROSPERO CRD 42019135115.

Conflict of interest statement

The authors declare that this study does not have any conflict of interest.

Figures

Figure 1
Figure 1
Risk of bias graph in included studies.
Figure 2
Figure 2
Risk of bias summary in included studies.
Figure 3
Figure 3
Forest plot of comparison: TYAT vs Placebo, outcome: TST.
Figure 4
Figure 4
Forest plot of comparison: TYAT vs Placebo, outcome: SE.
Figure 5
Figure 5
Forest plot of comparison: TYAT vs Placebo, outcome: SOL.
Figure 6
Figure 6
Forest plot of comparison: TYAT vs Placebo, outcome: WASO.
Figure 7
Figure 7
Forest plot of comparison: TYAT vs Placebo, outcome: PSQI.
Figure 8
Figure 8
Forest plot of comparison: TYAT vs Placebo, outcome: TCM curative efficacy.
Figure 9
Figure 9
Forest plot of comparison: TYAT vs Benzodiazepines, outcome: TCM curative efficacy.
Figure 10
Figure 10
Forest plot of comparison: TYAT vs Benzodiazepines, outcome: PSQI curative efficacy.
Figure 11
Figure 11
Forest plot of comparison: TYAT vs Non-benzodiazepine, outcome: PSQI.
Figure 12
Figure 12
Forest plot of comparison: TYAT vs Non-benzodiazepine, outcome: PSQI curative efficacy.

Similar articles

See all similar articles

References

    1. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017;13:307–49. - PMC - PubMed
    1. Sleep Disorder Section, Neurology Branch, Chinese Medical Association. Chinese Guideline for the Diagnosis and Treatment of Insomnia in Adults (2017 edition). Chin J Neurol 2018;51:324–35.
    1. Cao XL, Wang SB, Zhong BL, et al. The prevalence of insomnia in the general population in China: a meta-analysis. PloS One 2017;12:e0170772. - PMC - PubMed
    1. Nowicki Z, Grabowski K, Cubala WJ, et al. Prevalence of self-reported insomnia in general population of Poland. Psychiatr Pol 2016;50:165–73. - PubMed
    1. van de Straat V, Bracke P. How well does Europe sleep? A cross-national study of sleep problems in European older adults. Int J Public Health 2015;60:643–50. - PubMed

MeSH terms

Substances

Feedback